DYRK1A is associated with the control of cell growth and tumorigenesis, and it functions as a survival kinase in multiple cancer types, such as cervical cancer, pancreatic cancer and ovarian cancer.21 Meanwhile, DYRK1A inhibitors are considered potential candidates for cancer treatment.14, 22 As the role of DYRK1A played in NSCLC progression has not been identified, the goal of this work was to determine whether DYRK1A is a critical regulator in the development and treatment of NSCLC. The gene discussed is DYRK1A; the disease is pancreatic neoplasm.